
<p>Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases</p>
Author(s) -
Hongyu Xu,
Lin Zhou,
You Lü,
Xiaomei Su,
Cheng Peng,
Dong Liu,
Hui Gao,
Hua Li,
Weiwei Yuan,
Ling Zhang,
Tao Zhang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s230399
Subject(s) - medicine , nimotuzumab , erlotinib , epidermal growth factor receptor , lung cancer , oncology , epidermal growth factor , erlotinib hydrochloride , cancer research , receptor
Leptomeningeal metastases (LM) occur in 3-5% of patients with advanced non-small-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation during follow-up showed significant improvement in cancer symptoms and decreased tumor size in all three patients. Grade 3 and 4 toxicities were rarely seen. Based on apparent efficacy of the regimen and fewer side effects, we suggest that nimotuzumab in combination with erlotinib may be a promising option for the treatment of NSCLC with LM.